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BACKGROUND
Patients with recurrent or metastatic squamous-cell carcinoma of the head and 
neck after platinum chemotherapy have a very poor prognosis and limited thera-
peutic options. Nivolumab, an anti–programmed death 1 (PD-1) monoclonal anti-
body, was assessed as treatment for this condition.
METHODS
In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients 
with recurrent squamous-cell carcinoma of the head and neck whose disease had 
progressed within 6 months after platinum-based chemotherapy to receive nivolu-
mab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, 
single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary 
end point was overall survival. Additional end points included progression-free 
survival, rate of objective response, safety, and patient-reported quality of life.
RESULTS
The median overall survival was 7.5 months (95% confidence interval [CI], 5.5 to 9.1) 
in the nivolumab group versus 5.1 months (95% CI, 4.0 to 6.0) in the group that 
received standard therapy. Overall survival was significantly longer with nivolumab 
than with standard therapy (hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; 
P = 0.01), and the estimates of the 1-year survival rate were approximately 19 percent-
age points higher with nivolumab than with standard therapy (36.0% vs. 16.6%). 
The median progression-free survival was 2.0 months (95% CI, 1.9 to 2.1) with 
nivolumab versus 2.3 months (95% CI, 1.9 to 3.1) with standard therapy (hazard 
ratio for disease progression or death, 0.89; 95% CI, 0.70 to 1.13; P = 0.32). The 
rate of progression-free survival at 6 months was 19.7% with nivolumab versus 
9.9% with standard therapy. The response rate was 13.3% in the nivolumab group 
versus 5.8% in the standard-therapy group. Treatment-related adverse events of 
grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 
35.1% of those in the standard-therapy group. Physical, role, and social function-
ing was stable in the nivolumab group, whereas it was meaningfully worse in the 
standard-therapy group.
CONCLUSIONS
Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the 
head and neck, treatment with nivolumab resulted in longer overall survival than 
treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squibb; 
CheckMate 141 ClinicalTrials.gov number, NCT02105636.)
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Squamous-cell carcinoma of the head and neck is a major cause of cancer-asso-ciated illness and death, with more than 
600,000 cases diagnosed annually worldwide.1 
Most patients present with locoregionally ad-
vanced disease, and more than 50% have recur-
rence within 3 years.2-4 Patients with squamous-
cell carcinoma of the head and neck who have 
cancer progression within 6 months after plati-
num-based chemotherapy administered in the con-
text of primary or recurrent disease have a medi-
an survival of 6 months or less.5 No therapeutic 
options prolong survival among these patients.5,6
The recurrence and metastasis of squamous-
cell carcinoma of the head and neck are facili-
tated by immune evasion,7 which is mediated in 
part by expression of the programmed death 
ligands (PD-L1 and PD-L2) of the T-cell–suppres-
sive immune-checkpoint receptor programmed 
death 1 (PD-1).8-11 Nivolumab, a fully human IgG4 
anti–PD-1 monoclonal antibody, has shown anti-
tumor efficacy in multiple tumor types.12,13 We 
designed a randomized trial to investigate wheth-
er overall survival would be longer with nivolumab 
therapy than with standard therapy, among pa-
tients with platinum-refractory squamous-cell 
carcinoma of the head and neck.
Me thods
Patients
Eligible patients had histologically confirmed, 
recurrent squamous-cell carcinoma of the head 
and neck (including metastatic disease) of the 
oral cavity, pharynx, or larynx that was not ame-
nable to curative treatment; tumor progression 
or recurrence within 6 months after the last dose 
of platinum-containing chemotherapy adminis-
tered as adjuvant therapy or in the context of 
primary or recurrent disease; an age of at least 
18 years; an Eastern Cooperative Oncology Group 
performance-status score of 0 or 1 (on a scale 
from 0 to 5, with higher numbers indicating 
greater disability); adequate bone marrow, he-
patic, and renal function; and measurable dis-
ease according to Response Evaluation Criteria 
in Solid Tumors (RECIST), version 1.1.14 Major 
exclusion criteria were active brain metastases, 
autoimmune disease, or systemic immunosup-
pression; known human immunodeficiency virus 
or hepatitis B or C virus infection; and previous 
therapy targeting T-cell costimulating or immune-
checkpoint pathways.
Trial Design and Treatments
Patients were randomly assigned in a 2:1 ratio to 
receive intravenous nivolumab (Opdivo, Bristol-
Myers Squibb) or a standard, single-agent therapy 
of the investigator’s choice, with stratification 
according to receipt of previous cetuximab ther-
apy (yes or no). Nivolumab was administered at a 
dose of 3 mg per kilogram of body weight every 
2 weeks. Standard therapy consisted of weekly 
intravenous administration of methotrexate at a 
dose of 40 to 60 mg per square meter of body-
surface area, docetaxel at a dose of 30 to 40 mg per 
square meter, or cetuximab at a dose of 250 mg 
per square meter after a loading dose of 400 mg 
per square meter.
End Points and Assessments
The primary end point was overall survival, which 
was defined as the time from randomization to 
the date of death from any cause. Secondary end 
points were progression-free survival (time from 
randomization to the date of disease progres-
sion or death) and the rate of objective response 
according to RECIST, version 1.1. Additional pre-
specified end points included the time to re-
sponse; associations between PD-L1 level and 
human papillomavirus (HPV) status and overall 
survival, progression-free survival, and response 
rate; safety; and quality-of-life assessments.
Tumor response was assessed by investigators 
according to RECIST, version 1.1, every 6 weeks 
beginning at week 9. Patients were treated until 
an unacceptable level of drug-related toxic effects 
occurred or until disease progression. However, 
nivolumab treatment could be continued beyond 
disease progression, as assessed clinically or 
radiographically, if the investigator assessed that 
it was providing clinical benefit. Patients were 
followed for overall survival every 3 months until 
death, loss to follow-up, or withdrawal of consent.
At each treatment visit and for 100 days after 
receipt of the last dose, acute toxic effects were 
evaluated according to the Common Terminology 
Criteria for Adverse Events, version 4.0. Adverse 
events with potential immunologic causes were 
classified as select adverse events. The criteria 
for a dose delay or the discontinuation of nivolu-
mab or standard therapy because of treatment-
related adverse events were specified in the pro-
tocol, available with the full text of this article at 
NEJM.org. Dose modifications were not permit-
ted for nivolumab but were specified for metho-
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trexate, docetaxel, and cetuximab on the basis of 
the type and grade of the toxic effect.
Patient-reported outcomes, including symp-
toms and health-related quality of life, were ex-
ploratory end points and were evaluated with the 
use of the European Organization for Research 
and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire–Core 30 module (QLQ-C30) and 
the head-and-neck–specific module (QLQ-H&N35). 
Scores for these modules range from 0 to 100, 
with higher scores indicating better functioning 
or well-being or higher symptom burden, although 
scales measuring symptom burden were reverse-
scored to facilitate presentation. The propor-
tion of patients reporting health problems was 
assessed with the use of the three-level version 
of the European Quality of Life–5 Dimensions 
(EQ-5D-3L) questionnaire. Patients also com-
pleted the EQ-5D-3L visual-analogue scale, for 
which scores range from 0 to 100 and higher 
scores indicate better perceived health status.
Biomarker Analysis
Fresh or archived pretreatment tumor specimens 
were obtained after the last therapy and before 
trial entry from 90.6% of the patients. For pa-
tients with oropharyngeal cancer, tumor HPV 
status, assessed by means of p16 immunohisto-
chemical testing, was required to be documented 
by local or central analysis and was defined as 
positive if diffuse staining was present in at least 
70% of the tumor cells.15 Immunochemical test-
ing for p16 was not performed for nonoropha-
ryngeal cancers because of the low prevalence of 
HPV-positive tumors and poor specificity for HPV 
status at these anatomical sites.16 Tumor PD-L1 
membrane expression was evaluated centrally by 
means of immunohistochemical testing (Dako 
North America) with the use of a rabbit antihu-
man PD-L1 antibody (clone 28–8, Epitomics) and 
was scored at prespecified expression levels, in-
cluding levels of 1% or more, 5% or more, and 
10% or more in a minimum of 100 tumor cells 
that could be evaluated.17
Trial Oversight
This trial was registered with the National Can-
cer Institute and was approved by the institu-
tional review board at each participating institu-
tion. Written informed consent was obtained 
from all the patients before enrollment. The trial 
was designed by the academic authors in collabo-
ration with the sponsor (Bristol-Myers Squibb). 
The first and last authors attest to the accuracy 
and completeness of the data and analyses and 
vouch for adherence of the trial to the protocol. 
Medical-writing support, funded by the sponsor, 
was provided by inScience Communications and 
Chrysalis Medical Communications.
Statistical Analysis
We calculated the required number of events as-
suming one planned interim analysis of overall 
survival after 70% of the events occurred and 
stopping boundaries that were based on an 
O’Brien–Fleming alpha-spending function.18 We 
calculated that a sample of 360 patients and a 
total of 278 deaths would be required to ensure 
that a two-sided test procedure with one interim 
analysis, a 2:1 ratio for randomization, and an 
experiment-wide false positive rate of 5% would 
provide the trial with 90% power to detect a 
hazard ratio of 0.667 for the comparison of 
nivolumab with standard therapy.
Analyses of baseline characteristics and effi-
cacy followed the intention-to-treat principle. 
Analyses of dosing and safety were restricted to 
patients who received at least one dose of ther-
apy. The distributions of overall survival and 
progression-free survival were estimated by the 
Kaplan–Meier method and compared by means 
of log-rank tests stratified according to previous 
receipt of cetuximab (yes or no). Cox proportional-
hazards models (stratified according to status 
with respect to previous receipt of cetuximab) 
were used to estimate hazard ratios and com-
pute confidence intervals. A generalization of the 
Brookmeyer and Crowley method was used to 
compute confidence intervals for the median sur-
vival times, and the Borgan and Liestøl method 
was used to compute confidence intervals for 
survival at specific time points.19
A confidence interval of 97.73% was used for 
the hazard ratio for death in the analysis of 
overall survival to reflect the significance level 
for the interim comparison of overall survival. 
All other confidence intervals were calculated 
at the 95% level. The stratum-adjusted Cochran–
Mantel–Haenszel method was used to compute 
the odds ratio and the associated confidence 
interval for tumor response. The protocol speci-
fied that if nivolumab was shown to be superior 
to standard therapy with respect to overall sur-
vival, then progression-free survival and response 
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rate would each be tested, hierarchically at an 
alpha level of 5%, to ensure a false positive rate 
of no more than 5% for testing all three end 
points.
Prespecified analyses were performed to assess 
the consistency of treatment effect on the end 
points in a range of baseline subgroups, includ-
ing subgroups defined according to PD-L1 expres-
sion status and p16 status. A post hoc analysis 
of treatment effect in PD-L1 expression subgroups 
(≥1% vs. <1%) according to p16 status (positive 
vs. negative) was also performed. In addition, 
tests for interactions between treatment and 
PD-L1 expression level (prespecified) and be-
tween treatment and p16 status (post hoc) were 
performed. All these analyses were exploratory 
and descriptive: no adjustments for multiple com-
parisons were made, nor was the trial powered 
to detect interactions.
For patient-reported outcomes, a clinically 
meaningful change in score was regarded as 
10 points for the EORTC QLQ-C30 and QLQ-
H&N35 and as 7 points for the visual-analogue 
scale of the EQ-5D-3L questionnaire.20-22 Analy-
sis of covariance was used to compare the mean 
score changes between groups, with a separate 
analysis being performed for each patient-reported 
outcome. Each analysis was adjusted for treat-
ment, visit, status with respect to previous cetux-
imab use, and the baseline value of the patient-
reported outcome.
The data cutoff point for the analyses of over-
all survival, progression-free survival, and safety 
was December 18, 2015, which was the date of 
the planned interim analysis. Data on rate of 
response were based on a database lock on May 
5, 2016. At the interim analysis, the independent 
data monitoring committee confirmed that the 
P value for the comparison of overall survival was 
below the formal statistical boundary for signifi-
cance of 0.0227.
R esult s
Patients and Treatment
From June 2014 through August 2015, we ran-
domly assigned 240 patients to receive nivolu-
mab and 121 to receive standard therapy (Fig. S1 
in the Supplementary Appendix, available at 
NEJM.org). Previous treatment included radio-
therapy in 91.4% of the patients and two or more 
lines of systemic therapy in 54.5%. The treat-
ment groups were balanced with respect to most 
demographic and clinical characteristics (Table 1), 
although the standard-therapy group included 
higher percentages of patients 65 years of age or 
older and of patients who had never smoked. 
Tumor p16 status was reported, per protocol, for 
178 patients (113 patients in the nivolumab 
group and 65 in the standard-therapy group), 
and 26.2% of the patients in the nivolumab group 
and 24.0% in the standard-therapy group had 
positive p16 status.
Of 361 patients who underwent randomiza-
tion, 347 (96.1%) received one or more doses of 
assigned therapy (236 patients in the nivolumab 
group and 111 in the standard-therapy group). 
Standard therapies that were administered in-
cluded methotrexate (in 46 patients), docetaxel 
(in 52), and cetuximab (in 13). The median dura-
tion of treatment was 1.9 months in each group. 
Data on dose delays and reductions according to 
treatment group are provided in Table S1 in the 
Supplementary Appendix. At the time of analy-
sis, 41 of 236 patients (17.4%) were still receiving 
nivolumab and 3 of 111 (2.7%) were still receiv-
ing standard therapy.
Efficacy
Among 361 patients who underwent randomiza-
tion, 133 deaths (55.4% of patients) occurred in 
the nivolumab group and 85 deaths (70.2% of 
patients) occurred in the standard-therapy group. 
The median duration of follow-up for overall 
survival was 5.1 months (range, 0 to 16.8).
The median overall survival was 7.5 months 
(95% confidence interval [CI], 5.5 to 9.1) in the 
nivolumab group versus 5.1 months (95% CI, 
4.0 to 6.0) in the standard-therapy group. Overall 
survival was significantly longer with nivolumab 
than with standard therapy, and nivolumab-
treated patients had a risk of death that was 30% 
lower than the risk among patients assigned to 
standard therapy (hazard ratio, 0.70; 97.73% CI, 
0.51 to 0.96; P = 0.01) (Fig. 1A). The delayed 
separation of the Kaplan–Meier curves for over-
all survival is indicative of nonproportionality, 
and the hazard ratio should be thought of as an 
average over time.23 The estimated rate of overall 
survival at 1 year among patients treated with 
nivolumab (36.0%; 95% CI, 28.5 to 43.4) was 
more than double the rate with standard therapy 
(16.6%; 95% CI, 8.6 to 26.8).
Nivolumab was associated with longer median 
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Characteristic
Nivolumab 
(N = 240)
Standard Therapy 
(N = 121)
Total 
(N = 361)
Age
Median (range) — yr 59 (29–83) 61 (28–78) 60 (28–83)
≥75 yr — no. (%) 12 (5.0) 6 (5.0) 18 (5.0)
Male sex — no. (%) 197 (82.1) 103 (85.1) 300 (83.1)
Race — no. (%)†
White 196 (81.7) 104 (86.0) 300 (83.1)
Asian 29 (12.1) 14 (11.6) 43 (11.9)
Black 10 (4.2) 3 (2.5) 13 (3.6)
Other 5 (2.1) 0 5 (1.4)
Smoking or tobacco use — no. (%)
Current or former 191 (79.6) 85 (70.2) 276 (76.5)
Never 39 (16.2) 31 (25.6) 70 (19.4)
Not reported 10 (4.2) 5 (4.1) 15 (4.2)
ECOG performance-status score — no. (%)‡
0 49 (20.4) 23 (19.0) 72 (19.9)
1 189 (78.8) 94 (77.7) 283 (78.4)
≥2 1 (0.4) 3 (2.5) 4 (1.1)
Not reported 1 (0.4) 1 (0.8) 2 (0.6)
Site of primary tumor — no. (%)
Larynx 34 (14.2) 15 (12.4) 49 (13.6)
Oral cavity 108 (45.0) 67 (55.4) 175 (48.5)
Pharynx 92 (38.3) 36 (29.8) 128 (35.5)
Other§ 6 (2.5) 3 (2.5) 9 (2.5)
No. of previous lines of systemic cancer  
therapy — no. (%)¶
1 106 (44.2) 58 (47.9) 164 (45.4)
2 80 (33.3) 45 (37.2) 125 (34.6)
≥3 54 (22.5) 18 (14.9) 72 (19.9)
Context of previous systemic therapy  
regimen — no. (%)‖
Adjuvant therapy 37 (15.4) 21 (17.4) 58 (16.1)
Neoadjuvant therapy 17 (7.1) 16 (13.2) 33 (9.1)
Primary disease 173 (72.1) 83 (68.6) 256 (70.9)
Metastatic disease 112 (46.7) 59 (48.8) 171 (47.4)
Previous receipt of cetuximab — no. (%) 150 (62.5) 72 (59.5) 222 (61.5)
*  There were no significant (P<0.05) between-group differences in the characteristics listed here, except for smoking 
(P = 0.047). Percentages may not total 100 because of rounding.
†  Race was self-reported.
‡  Eastern Cooperative Oncology Group (ECOG) performance status is scored on a scale from 0 to 5, with higher num-
bers indicating greater disability.
§  The “Other” category included patients with a tumor in more than one of the categories (i.e., larynx, oral cavity, or pharynx).
¶  A line of systemic chemotherapy was defined as any chemotherapy that was administered as part of primary therapy for 
squamous-cell carcinoma of the head and neck (e.g., induction or concurrent chemoradiotherapy) or any single-agent 
or multiple-agent chemotherapy regimen that was administered after a diagnosis of recurrent squamous-cell carcinoma 
of the head and neck.
‖  Patients may have received previous systemic therapy in more than one context.
Table 1. Characteristics at Baseline and Previous Therapy.*
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overall survival than all the options for standard 
therapy: methotrexate (median, 4.6 months; haz-
ard ratio for death, 0.64; 95% CI, 0.43 to 0.96), 
docetaxel (median, 5.8 months; hazard ratio, 
0.82; 95% CI, 0.53 to 1.28), and cetuximab (me-
dian, 4.1 months; hazard ratio, 0.47; 95% CI, 
0.22 to 1.01). Across prespecified demographic 
and clinical subgroups, the estimate of the haz-
ard ratio for death in the analysis of overall 
survival with nivolumab versus standard therapy 
was less than 1 (Fig. 1C, and Fig. S2 in the 
Supplementary Appendix).
No significant difference between groups was 
observed with regard to the rate of progression-
free survival (hazard ratio for disease progres-
sion or death, 0.89; 95% CI, 0.70 to 1.13; P = 0.32). 
The crossing of the Kaplan–Meier curves is in-
dicative of nonproportionality. The median pro-
gression-free survival was 2.0 months (95% CI, 
1.9 to 2.1) in the nivolumab group versus 2.3 
months (95% CI, 1.9 to 3.1) in the standard-
therapy group (Fig. 1B). However, a late separa-
tion in the Kaplan–Meier curves was observed, 
and the estimated rates of progression-free sur-
vival at 6 months were 19.7% (95% CI, 14.6 to 
25.4) in the nivolumab group and 9.9% (95% CI, 
5.0 to 16.9) in the standard-therapy group.
The response rate among nivolumab-treated 
patients was 13.3% (95% CI, 9.3 to 18.3), includ-
ing 6 complete responses and 26 partial respons-
es. In the standard-therapy group, the response 
rate was 5.8% (95% CI, 2.4 to 11.6), including 
1 complete response and 6 partial responses. The 
median time to response was 2.1 months with 
nivolumab versus 2.0 months with standard 
therapy. Tumor reductions were more durable 
with nivolumab, as indicated by the tumor-burden 
plots over time for patients who had either a 
partial response or a complete response (Fig. S3 
in the Supplementary Appendix).
PD-L1 Expression and p16 Status
A prespecified, exploratory analysis was per-
formed to evaluate the consistency of the treat-
ment effect in subgroups defined according to 
tumor PD-L1 expression level (≥1% vs. <1%) 
(Table 2). Tumor PD-L1 expression status could 
be evaluated in 260 of 361 patients (72.0%) 
(Table S2 in the Supplementary Appendix). Among 
the patients who could be evaluated, 57.3% had a 
PD-L1 expression level of 1% or more.
In the analysis of overall survival in the sub-
group of patients with a PD-L1 expression level 
of 1% or more, the hazard ratio for death among 
patients treated with nivolumab versus standard 
therapy was 0.55 (95% CI, 0.36 to 0.83) (Fig. 2A), 
whereas in the subgroup of patients with a PD-
L1 expression level of less than 1%, the hazard 
ratio was 0.89 (95% CI, 0.54 to 1.45; P = 0.17 for 
interaction) (Fig. 2B). The estimates of the haz-
ard ratio for death in the analysis of overall 
survival in the subgroups of patients with PD-L1 
expression levels of 5% or more and of 10% or 
more were similar to those among patients with 
PD-L1 expression levels of 1% or more (Table 2).
In our post hoc exploratory analysis involving 
the 178 patients for whom tumor p16 status was 
reported, the median overall survival appeared 
to be longer with nivolumab than with standard 
therapy regardless of p16 status (Table 2). Among 
patients with p16-positive tumors, the median 
overall survival was 9.1 months in the nivolumab 
group versus 4.4 months in the standard-therapy 
group (hazard ratio for death, 0.56; 95% CI, 0.32 
to 0.99); among patients with p16-negative tu-
mors, the median overall survival was 7.5 versus 
5.8 months (hazard ratio, 0.73; 95% CI, 0.42 to 
1.25; P = 0.55 for interaction) (Figs. S4 and S5 in 
the Supplementary Appendix).
We further explored the effect of nivolumab 
versus standard therapy on overall survival in 
subgroups defined according to both PD-L1 ex-
pression (≥1% vs. <1%) and tumor p16 status 
(positive vs. negative) (Table 2). The estimated 
hazard ratios for death in the analysis of overall 
survival with nivolumab versus standard therapy 
were less than 1 in all four subgroups. Results 
of the exploratory analysis of the treatment ef-
fect on response rates in the subgroups defined 
according to tumor PD-L1 level and p16 status 
are provided in Table S3 in the Supplementary 
Appendix.
Safety
The most common treatment-related adverse 
events are shown in Table 3 (see also Tables S4, 
S5, and S6 in the Supplementary Appendix). The 
rates of treatment-related adverse events of any 
grade were similar in the two groups, but fewer 
events of grade 3 or 4 were reported in the 
nivolumab group than in the standard-therapy 
group (occurring in 13.1% vs. 35.1% of patients). 
In the nivolumab group, the most frequent ad-
verse events of any grade were fatigue, nausea, 
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rash, decreased appetite, and pruritus. Among 
the select adverse events, gastrointestinal events 
were less common with nivolumab than with 
standard therapy (occurring in 6.8% vs. 14.4% of 
the patients; primarily diarrhea), whereas ad-
verse events of the skin were more common with 
nivolumab (in 15.7% vs. 12.6%; primarily rash 
and pruritus), as were adverse events of the endo-
crine system (in 7.6% vs. 0.9%; primarily hypo-
thyroidism). Pneumonitis was observed in 2.1% 
of the patients treated with nivolumab. Two 
treatment-related deaths were reported in the 
nivolumab group (pneumonitis and hypercalce-
mia in one patient each), and one patient in the 
standard-therapy group died from a treatment-
related lung infection.
Variable
Nivolumab 
(N = 240)
Standard Therapy 
(N = 121)
Hazard Ratio for Death 
(95% CI)
Patients Median Survival Patients Median Survival
no. (%) mo no. (%) mo
All patients 240 (100.0) 7.5 121 (100.0) 5.1 0.69 (0.53–0.91)
PD-L1 expression level
≥1% 88 (36.7) 8.7 61 (50.4) 4.6 0.55 (0.36–0.83)
≥5% 54 (22.5) 8.8 43 (35.5) 4.6 0.50 (0.30–0.83)
≥10% 43 (17.9) 8.7 34 (28.1) 5.2 0.56 (0.31–1.01)
<1% 73 (30.4) 5.7 38 (31.4) 5.8 0.89 (0.54–1.45)
<5% 107 (44.6) 7.0 56 (46.3) 5.1 0.81 (0.55–1.21)
<10% 118 (49.2) 7.2 65 (53.7) 4.6 0.73 (0.50–1.06)
Not quantifiable 79 (32.9) 7.8 22 (18.2) 5.8 0.79 (0.44–1.44)
p16 status
Positive 63 (26.2) 9.1 29 (24.0) 4.4 0.56 (0.32–0.99)
Negative 50 (20.8) 7.5 36 (29.8) 5.8 0.73 (0.42–1.25)
Combined subgroup
PD-L1 ≥1% and p16-positive 23 (9.6) 8.8 14 (11.6) 3.9 0.50 (0.21–1.19)
PD-L1 ≥1% and p16-negative 17 (7.1) 8.8 16 (13.2) 5.6 0.44 (0.18–1.10)
PD-L1 <1% and p16-positive 24 (10.0) 10.0 10 (8.3) 6.4 0.55 (0.22–1.39)
PD-L1 <1% and p16-negative 14 (5.8) 7.1 12 (9.9) 7.4 0.82 (0.31–2.19)
*  Expression of the programmed death 1 ligand 1 (PD-L1) was measured in 260 patients (161 patients in the nivolumab group and 99 in the 
standard-therapy group), and the p16 level in 178 patients (113 in the nivolumab group and 65 in the standard-therapy group). Hazard ratios 
are from unstratified Cox proportional-hazards models.
Table 2. Exploratory Analysis of Overall Survival According to Tumor PD-L1 Expression and p16 Status Subgroups.*
Figure 1 (facing page). Overall Survival, Progression-free Survival, and Treatment Effect on Overall Survival  
According to Subgroup.
Panel A shows the Kaplan–Meier curves for overall survival among all the patients who underwent randomization 
and were assigned to receive either nivolumab or standard therapy. In the planned interim analysis, the boundary 
for statistical significance for overall survival required the P value to be less than 0.0227. Panel B shows the Kaplan–
Meier curves for progression-free survival among all the patients who underwent randomization. Symbols indicate 
censored observations. Hazard ratios (and confidence intervals) were computed with the use of a stratified Cox pro-
portional-hazards model, and the P values were from a stratified log-rank test. Panel C shows a forest plot of un-
stratified hazard ratios for death in the analysis of the treatment effect according to demographic and clinical sub-
groups at baseline. Hazard ratios were not calculated for subgroups that included fewer than 20 patients across the 
two groups. Platinum-refractory disease in the context of primary therapy refers to cancer progression within 6 months 
after platinum therapy administered in the context of primary or adjuvant therapy (a post hoc derived analysis).
The New England Journal of Medicine 
Downloaded from nejm.org at INSTITUTE FOR CANCER RESEARCH on April 5, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;19 nejm.org November 10, 20161864
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Figure 2. Overall Survival According to Baseline PD-L1 Status and Quality of Life and Symptom Burden.
Kaplan–Meier curves for overall survival according to tumor programmed death 1 ligand 1 (PD-L1) expression of 1% or higher and of less than 
1% are shown in Panels A and B, respectively. Symbols indicate censored observations. Hazard ratios (and 95% confidence intervals) were 
computed with the use of a Cox proportional-hazards model. Panel C shows the results of multivariable analyses of adjusted mean changes 
from baseline in patient-reported outcomes at weeks 9 and 15, stratified according to treatment group, for 129 patients with questionnaire 
responses. Least-squares mean estimates were based on analyses of covariance of changes in scores from baseline with adjustment for treat-
ment group, visit, status with respect to previous cetuximab use, and baseline score. Physical, role, and social functioning were assessed by 
means of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core 30 module (QLQ-
C30), and pain, sensory problems, and social-contact problems were assessed by means of the EORTC head-and-neck–specific module 
(QLQ-H&N35). All scales range from 0 to 100 and were scored such that higher values indicated better functioning or lower symptom burden. 
A clinically meaningful score change was regarded as one of 10 points (dashed lines) or more.21,22 I bars indicate 95% confidence intervals.
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Patient-Reported Outcomes
Patient-reported quality-of-life measures were 
similar at baseline among patients randomly as-
signed to the nivolumab group and those as-
signed to the standard-therapy group (Table S7 
in the Supplementary Appendix). Analyses were 
limited to data collected through week 15 owing 
to a low number of responses to the question-
naires in the standard-therapy group after that 
time point (Table S8 in the Supplementary Ap-
pendix). Patients in the standard-therapy group 
reported clinically meaningful worsening of phys-
ical, role, and social functioning (as assessed by 
means of the QLQ-C30), as well as of pain, 
sensory problems, and social-contact problems 
(as assessed by means of the QLQ-H&N35). Con-
versely, among patients treated with nivolumab, 
these measures remained nearly stable or showed 
slight improvements. P values showed significant 
between-group differences at both week 9 and 
week 15 for most comparisons (Fig. 2C). Addi-
tional patient-reported outcome data, including 
health problems and evaluations of health as 
measured by the EQ-5D-3L questionnaire, are 
provided in Table S9 in the Supplementary Ap-
pendix.
Discussion
Among patients with recurrent squamous-cell 
carcinoma of the head and neck who had dis-
ease progression after platinum-based chemo-
therapy, treatment with nivolumab resulted in 
significantly longer survival than treatment with 
standard therapy. Patients who were treated with 
nivolumab had stability in several measures of 
quality of life, whereas the patients who received 
standard therapy had declines in these measures.
Our exploratory biomarker analysis indicated 
that patients who were treated with nivolumab 
appeared to have longer overall survival than 
those treated with standard therapy, regardless of 
tumor PD-L1 expression or p16 status. Although 
we observed preliminary evidence that patients 
with a tumor PD-L1 expression level of 1% or 
more or p16-positive tumors (or both) may have 
Event Nivolumab (N = 236) Standard Therapy (N = 111)
Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
number of patients (percent)
Any event 139 (58.9)* 31 (13.1) 86 (77.5)† 39 (35.1)
Fatigue 33 (14.0) 5 (2.1) 19 (17.1) 3 (2.7)
Nausea 20 (8.5) 0 23 (20.7) 1 (0.9)
Rash 18 (7.6) 0 5 (4.5) 1 (0.9)
Decreased appetite 17 (7.2) 0 8 (7.2) 0
Pruritus 17 (7.2) 0 0 0
Diarrhea 16 (6.8) 0 15 (13.5) 2 (1.8)
Anemia 12 (5.1) 3 (1.3) 18 (16.2) 5 (4.5)
Asthenia 10 (4.2) 1 (0.4) 16 (14.4) 2 (1.8)
Vomiting 8 (3.4) 0 8 (7.2) 0
Dry skin 7 (3.0) 0 10 (9.0) 0
Stomatitis 5 (2.1) 1 (0.4) 10 (9.0) 3 (2.7)
Weight loss 4 (1.7) 0 6 (5.4) 0
Mucosal inflammation 3 (1.3) 0 14 (12.6) 2 (1.8)
Peripheral neuropathy 1 (0.4) 0 7 (6.3) 0
Alopecia 0 0 14 (12.6) 3 (2.7)
Neutropenia 0 0 9 (8.1) 8 (7.2)
*  Data include one patient with a grade 5 event of hypercalcemia and one patient with grade 3 pneumonitis who subse-
quently died of a grade 5 pulmonary embolism.
†  Data include one patient with a grade 5 event of lung infection.
Table 3. Treatment-Related Adverse Events Occurring in at Least 5% of the Patients in Either Group.
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a greater magnitude of effect from nivolumab 
therapy than those whose PD-L1 level was less 
than 1% or who had p16-negative tumors, the 
interactions were not significant and were not 
corrected for multiple comparisons. The response 
data from this trial are consistent with those 
from a previous phase 1b trial of anti–PD-1 
therapy.24,25
In conclusion, nivolumab prolonged survival, 
as compared with standard therapy, among pa-
tients with platinum-refractory squamous-cell 
carcinoma of the head and neck. Nivolumab was 
associated with fewer toxic effects of grade 3 or 
4 than standard therapy (13.1% vs. 35.1%) and 
with maintenance of quality of life among pa-
tients with a treatment-refractory cancer that 
otherwise has serious adverse effects on quality 
of life as it leads to death.
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